At its recent annual Science Day, Moderna signaled a profound strategic shift, moving beyond its foundational infectious disease vaccine and…
Read More
Verseon bets physics can take drug design beyond AI’s training data
Bay Area-based pharmaceutical company Verseon has been a quiet pioneer in computational drug design since 2002, predating the widespread emergence…
Read More
Moderna bets on mRNA’s second act with cancer, autoimmune programs and AI research platform
At its recent annual Science Day, biotechnology giant Moderna signaled a profound strategic expansion beyond its highly successful infectious disease…
Read More
Moderna bets on mRNA’s second act with cancer, autoimmune programs and AI research platform
Moderna, the biotechnology firm that gained global prominence for its mRNA-based COVID-19 vaccine, is embarking on a significant strategic pivot,…
Read More
Bristol Myers Squibb Bets on Milvexian and Cobenfy to Drive Growth into the 2030s Amidst Patent Expiries
Bristol Myers Squibb (BMS) is strategically positioning itself for sustained growth through the 2030s, with upcoming pivotal Phase III readouts…
Read MoreYOU MAY HAVE MISSED
